Search Results - "JEYAPALAN, Suriya A"

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma by Lacouture, Mario E., Anadkat, Milan J., Ballo, Matthew T., Iwamoto, Fabio, Jeyapalan, Suriya A., La Rocca, Renato V., Schwartz, Margaret, Serventi, Jennifer N., Glas, Martin

“…Importance: Tumor Treating Fields (TTFields) are an anti-mitotic treatment approved for treating newly diagnosed and recurrent glioblastoma, and mesothelioma…”
Get full text

A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872 by Galanis, Evanthia, Anderson, S. Keith, Twohy, Erin L., Carrero, Xiomara W., Dixon, Jesse G., Tran, David Dinh, Jeyapalan, Suriya A., Anderson, Daniel M., Kaufmann, Timothy J., Feathers, Ryan W., Giannini, Caterina, Buckner, Jan C., Anastasiadis, Panos Z., Schiff, David

“…Background Src signaling is markedly upregulated in patients with invasive glioblastoma (GBM) after the administration of bevacizumab. The Src family kinase…”
Get full text

Management of Brain Metastases by Jeyapalan, Suriya A., Batchelor, Tracy

“…Advances in neurosurgery and the development of stereotactic radiosurgery have expanded treatment options available for patients with brain metastases…”
Get full text

Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma by Shi, Wenyin, Roberge, David, Kleinberg, Lawrence, Jeyapalan, Suriya A., Goldlust, Samuel Aaron, Nagpal, Seema, Lustgarten, Leonardo, Combs, Stephanie E, Nishikawa, Ryo, Reardon, David A., Grossman, Rachel, Glas, Martin

“…TPS2083 Background: Tumor Treating Fields (TTFields) therapy, a noninvasive and locoregional antimitotic cancer treatment modality, is approved for newly…”
Get full text

Presenting symptoms and patient prognosticators in neoplastic meningitis: A single institution experience by Ghatnekar, Shilpa, Hachem, Hilal, Patel, Rima, Dowd, Richard, Godara, Amandeep, Chang, Hong, Jeyapalan, Suriya A.

“…Abstract only e13593 Background: Neoplastic meningitis (NM) occurs in 5-15% of cancer patients, with less than 15% surviving one year. Untreated, median…”
Get full text

Abstract CT258: EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide +/- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma by Shi, Wenyin, Kleinberg, Lawrence, Jeyapalan, Suriya A., Goldlust, Samuel A., Nagpal, Seema, Combs, Stephanie E., Roberge, David, Nishigawa, Ryo, Grossman, Rachel, Glas, Martin

“…Purpose: Tumor treating fields (TTFields) is a non-invasive, loco-regional antimitotic treatment approved as a standard-of-care for newly diagnosed…”
Get full text

Analysis of the EF-14 phase III trial reveals that tumor treating fields alter progression patterns in glioblastoma by Jeyapalan, Suriya A., Toms, Steven A, Hottinger, Andreas Felix, Kleinberg, Lawrence, Pollom, Erqi, Soltys, Scott G., Glas, Martin

“…Abstract only 2055 Background: The EF-14 [NCT00916409] trial showed that addition of alternating electric fields (Tumor Treating Fields, TTFields) to…”
Get full text

Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma by Shi, Wenyin, Kleinberg, Lawrence, Jeyapalan, Suriya A., Goldlust, Samuel Aaron, Nagpal, Seema, Reardon, David A., Combs, Stephanie E, Roberge, David, Nishigawa, Ryo, Glas, Martin

“…Abstract only TPS2580 Background: Tumor treating fields (TTFields) is a non-invasive, regional antimitotic treatment approved as a standard of care for…”
Get full text

Diagnostic Evaluation of Neurologic Metastases by Jeyapalan, Suriya A., Batchelor, Tracy T.

Get full text

CTNI-74. PHASE 3 TRIDENT TRIAL: CONCOMITANT RADIATION THERAPY (RT) AND TEMOZOLOMIDE +/- TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA by Shi, Wenyin, Kleinberg, Lawrence, Jeyapalan, Suriya A, Goldlust, Samuel, Nagpal, Seema, Combs, Stephanie E, Roberge, David, Nishigawa, Ryo, Grossman, Rachel, Glas, Martin

Get full text

Immunomodulation of glioma cells after gene therapy : Induction of major histocompatibility complex Class I but not Class II antigen in vitro by PARSA, Andrew T, CHI, John H, HURLEY, Patrick T, JEYAPALAN, Suriya A, BRUCE, Jeffrey N, PIEPMEIER, Joseph M, RAFFEL, Corey, GLICK, Roberta P, LICHTOR, Terry, RUTKA, James T

“…Acquired immunity has been demonstrated in Fischer rats bearing syngeneic 9L tumors after herpes simplex virus (HSV) thymidine kinase (TK) gene transfection…”
Get full text

A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872 by Galanis, Evanthia, Anderson, S. Keith, Twohy, Erin L., Carrero, Xiomara W., Dixon, Jesse G., Tran, David Dinh, Jeyapalan, Suriya A., Anderson, Daniel M., Kaufmann, Timothy J., Feathers, Ryan W., Giannini, Caterina, Buckner, Jan C., Anastasiadis, Panos Z., Schiff, David

“…In a randomized comparative phase II trial in recurrent GBM the combination the Src inhibitor dasatinib with bevacizumab led to PFS6 rate that was numerically…”
Get full text

Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations by Brastianos, Priscilla Kaliopi, Twohy, Erin, Gerstner, Elizabeth Robins, Kaufmann, Timothy J., Iafrate, A. John, Jeyapalan, Suriya A., Piccioni, David Eric, Lassman, Andrew B., Fadul, Camilo E., Schiff, David, Taylor, Jennie Webster, Chowdhary, Sajeel A., Kaley, Thomas Joseph, Morrison, Tara, Kumthekar, Priya, Geyer, Susan, Cahill, Daniel P., Santagata, Sandro, Barker, Frederick G., Galanis, Evanthia

“…Abstract only 2502 Background: Patients with progressive or recurrent meningiomas have limited treatment options. Clinical trials of systemic therapies for…”
Get full text

CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32) by Shi, Wenyin, Kleinberg, Lawrence, Jeyapalan, Suriya A, Goldlust, Samuel A, Nagpal, Seema, Roberge, David, Nishikawa, Ryo, Grossman, Rachel, Glas, Martin

Get full text

Abstract CT061: TRIDENT phase 3 study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma by Shi, Wenyin, Kleinberg, Lawrence, Jeyapalan, Suriya A., Goldlust, Samuel A., Nagpal, Seema, Lustgarten, Leonardo, Combs, Stephanie E., Roberge, David, Nishikawa, Ryo, Reardon, David, Grossman, Rachel, Glas, Martin

“…Background: Tumor Treating Fields (TTFields) therapy is a loco-regional, noninvasive treatment approved for newly diagnosed (nd)/recurrent (r) glioblastoma…”
Get full text

Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment by Malani, Rachna, Fleisher, Martin, Lin, Xuling, Omuro, Antonio Marcilio Padula, Groves, Morris D., Lin, Nancy U., Melisko, Michelle E., Lassman, Andrew B., Jeyapalan, Suriya A., Briggs, Samuel, DeAngelis, Lisa Marie, Raizer, Jeffrey J., Pentsova, Elena

“…Abstract only 11549 Background: The validated CellSearch system (Janssen Diagnostics, LLC), utilizing an immunomagnetic CTC selection method based on EPCAM…”
Get full text

NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM) by Galanis, Evanthia, Anderson, S. Keith, Anastasiadis, Panagiotis, Tran, David Dinh, Jeyapalan, Suriya A., Anderson, Daniel M., Kaufmann, Timothy J., Giannini, Caterina, Buckner, Jan C., Schiff, David

“…Abstract only…”
Get full text

Immunomodulation of Glioma Cells after Gene Therapy: Induction of Major Histocompatibility Complex Class I but Not Class II Antigen in Vitro by Parsa, Andrew T., Chi, John H., Hurley, Patrick T., Jeyapalan, Suriya A., Bruce, Jeffrey N.

Get full text